跳到主要导航
跳到搜索
跳到主要内容
Pure University (For Demo Only) 国内
帮助和常见问题
English
中文
国内
简介
研究单位
科研成果
设备
数据集
活动
奖项
影响
项目
新闻 / 媒体
按专业知识、名称或附属进行搜索
联系专家
查看 Scopus 资料
Liwski Robert Stefan
Assistant Professor
Dalhousie University
,
Computer Science
电子邮件
LR978543
dal
ca
网站
https://www.scopus.com/authid/detail.url?authorId=6601978543
h-index
h10-index
h5-index
1940
引用
25
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
720
引用
16
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
56
引用
5
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
1999
2023
每年的科研成果
综述
指纹
网络
科研成果
(68)
新闻 / 媒体
(1)
相似简介
(6)
指纹
深入其中 Liwski Robert Stefan 为活跃的研究主题。这些主题标签来自此人的成果。它们共同形成唯一的指纹。
分类
加权
按字母排序
Keyphrases
HLA Antibodies
29%
Infusion Model
25%
Induced Proliferation
25%
Aggressive Systemic Mastocytosis
25%
Transgenic Zebrafish Model
25%
Calculated Panel Reactive Antibody
25%
CPRA
25%
Unacceptable Antigen
25%
Microparticles
25%
Living Donor Evaluation
25%
Cellular Origin
25%
Red Blood Cell Antigens
25%
Neointimal
25%
Lymphocyte Morphology
25%
Allograft Vasculopathy
25%
Neointimal Lesion
25%
Predictive Significance
25%
Surgical Adhesions
25%
Immunological Synapse
25%
Cancer Defense
25%
Cord Blood Unit
25%
Donation Decisions
25%
Acute Phase Proteins
25%
Hepcidin
25%
Donor Selection
25%
Kidney Allograft Survival
25%
Unrelated Donor
25%
Hydrophobic Mismatch
25%
Myeloid Disorders
25%
Normal Hematopoiesis
25%
Mean Fluorescence Intensity
25%
C1q Binding
25%
Allospecific
25%
T Cytotoxic Cells
25%
Lymphocyte Activity
25%
Vav1
25%
Endothelial Protein C Receptor
25%
Macrophage Invasion
25%
Flow Crossmatch
25%
Chronic Antibody-mediated Rejection
25%
Negative Flow
25%
Ischemic Flap
25%
Breast Cancer
25%
Pubertal Maturation
25%
Eosinophils
25%
Assay Protocol
25%
Single Antigen Bead
25%
SAB Assay
25%
Multiplex Bead Assay
25%
Complement-dependent Cytotoxicity
25%
Immunology and Microbiology
HLA Antibody
100%
Human Leukocyte Antigen
75%
Peptide Vaccine
50%
Transplant Procedure
41%
Immunoassay
40%
Complement Component C3d
40%
Epitope
33%
Cancer Vaccine
27%
Transgenic Zebrafish
25%
Regulatory T Cell
25%
T Cell Activation
25%
Erythrocyte Antigen
25%
Allotransplantation
25%
Immunological Synapse
25%
Immunoglobulin M
25%
Complement Component C1q
25%
Vaccine Efficacy
25%
Immune Complex
25%
Naive T Cell
25%
Antibody Mediated Rejection
25%
Immunotherapy
25%
Immunomodulation
25%
B Cell
25%
Eosinophil Granulocyte
25%
Complement Dependent Cytotoxicity
25%
Incubation Temperature
25%
Cell Transplantation
25%
Granzyme B
25%
Tumor Cell
25%
B Lymphocyte Activation
25%
Polyinosinic:polycytidylic Acid
25%
High Throughput Sequencing
25%
Allograft Vasculopathy
16%
B Cell Activation
16%
Dilution
15%
Stem Cell
12%
Cytotoxicity
12%
Dendritic Cell
12%
Mouse Model
12%
Engraftment
12%
CD86
11%
Immune System
10%
Ethylenediaminetetraacetic Acid
10%
Eosinophil
10%
Solid
9%
Immunogenicity
8%
Immune Injury
8%
Tunica Media
8%
CD80
8%
Cell Cycle
8%
Medicine and Dentistry
Human Leukocyte Antigen
75%
Allograft
50%
Cell Transplantation
50%
Blood Product
50%
Antigen Antibody Complex
50%
Blood Transfusion
35%
Peptide Vaccine
25%
Lymphocytosis
25%
Immunological Synapse
25%
Donor Selection
25%
DNA (Cytosine 5) Methyltransferase
25%
Hematopoietic Stem Cell
25%
Methyltransferase Inhibitor
25%
Kidney Allograft
25%
Epigenetic Therapy
25%
Endothelial Protein C Receptor
25%
Alloantibody
25%
Distal Tibia
25%
Malignant Neoplasm
25%
Complement Component C3d
25%
B Lymphocyte Activation
25%
Polyinosinic Polycytidylic Acid
25%
Allograft Vasculopathy
16%
B Cell Activation
16%
Edetic Acid
15%
Sensitization
14%
Lymph Node Cell
12%
Enzyme Linked Immunospot Assay
12%
Stem Cell
12%
Antibody Mediated Rejection
12%
Engraftment
12%
Density Gradient Centrifugation
12%
HLA Antibody
12%
Anthrax
12%
Lymphocyte Structure
10%
Matched Donor
10%
Myeloproliferative Disorder
8%
Immune Injury
8%
Rational Emotive Behavior Therapy
8%
Platelet
8%
Cell Expansion
8%
Preleukemia
8%
Erythrocyte
8%
Toll Like Receptor 3
8%
Toll Like Receptor
8%
Computer Assisted Tomography
7%
Recurrent Shoulder Dislocation
7%
Bone Allograft
6%
Osteolysis
6%
Microvascular Surgery
6%
